Assembly Biosciences, Inc.
NASDAQ:ASMB
Overview | Financials
Company Name | Assembly Biosciences, Inc. |
Symbol | ASMB |
Currency | USD |
Price | 14.21 |
Market Cap | 90,322,881 |
Dividend Yield | 0% |
52-week-range | 9.84 - 19.93 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jason A. Okazaki |
Website | https://www.assemblybio.com |
An error occurred while fetching data.
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD